Price$8.74+0.19 (+2.22%)
2026-03-042026-06-05
News · 26 weeks63+111%
2025-12-142026-06-07
Mix3790d
- Insider13(35%)
- Other9(24%)
- Earnings7(19%)
- SEC Filings7(19%)
- Analyst1(3%)
Latest news
25 items- PRKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 1, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 53,000 shares of common stock to four (4) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4)
- INSIDERSEC Form 4 filed by Director Parks Diane L.4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Director Collins Helen Louise4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Director Hasnain Faheem4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Director Vasconcelles Michael4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Director Szela Mary T4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Director Malley Thomas4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Director Schafer Carol4 - Kura Oncology, Inc. (0001422143) (Issuer)
- SECSEC Form S-8 filed by Kura Oncology Inc.S-8 - Kura Oncology, Inc. (0001422143) (Filer)
- SECKura Oncology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Kura Oncology, Inc. (0001422143) (Filer)
- PRKura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – – Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients – – Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors – – New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings – – First planned platform combination, darlifarnib + da
- PRKura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months – – Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure – – Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed – SAN DIEGO and TOKYO, June 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced the publication in Blood of updated resul
- SECSEC Form DEFA14A filed by Kura Oncology Inc.DEFA14A - Kura Oncology, Inc. (0001422143) (Filer)
- PRKura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib's potential as a precision combination agent across targeted therapies – – Clear clinical activity in KRASi-experienced patients and manageable safety profile – – Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET – SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today reported compelling first-in-human data fro
- INSIDERChief Commercial Officer Powl Brian T. sold $110,000 worth of shares (10,000 units at $11.00) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 173,614 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERChief Legal Officer Bair Teresa Brophy sold $21,160 worth of shares (2,256 units at $9.38) as part of a pre-agreed trading plan, decreasing direct ownership by 0.98% to 226,931 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERChief Commercial Officer Powl Brian T. sold $3,122 worth of shares (339 units at $9.21) as part of a pre-agreed trading plan, decreasing direct ownership by 0.18% to 183,614 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERChief Operating Officer Ford Kathleen sold $20,483 worth of shares (2,257 units at $9.08) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 153,560 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- PRKura Oncology to Present at TD Cowen 7th Annual Oncology Innovation SummitSAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA) today announced its participation in the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura management is scheduled to participate in a virtual fireside chat at 1:30 p.m. ET / 10:30 a.m. PT on May 26, 2026. The live webcast and archived replay of the event may be accessed on the Investors section of the Company's website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura's pipeline of small molecule drug candidates is designed to target cancer signaling
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kura Oncology Inc.SCHEDULE 13G/A - Kura Oncology, Inc. (0001422143) (Subject)
- SECSEC Form 10-Q filed by Kura Oncology Inc.10-Q - Kura Oncology, Inc. (0001422143) (Filer)
- SECKura Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kura Oncology, Inc. (0001422143) (Filer)
- PRKura Oncology Reports First Quarter 2026 Financial Results– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives – – Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML – – $580.8 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program through first topline KOMET-017 Phase
- PRKura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable responses with median duration of CRc not reached in NPM1-m patients at ~15 months median follow-up – – Phase 3 KOMET-017 trial currently enrolling with potential for accelerated FDA review in 2028 – – Virtual Kura investor call on June 3 at 8:00 a.m. ET – SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced that updated results from the frontline arm of the Phase 1 KOMET-007 (NCT0573518
- PRKura Oncology to Participate in Bank of America Securities Healthcare ConferenceSAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Bank of America Securities 2026 Healthcare Conference. Kura management is scheduled to participate in a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT on May 13, 2026. The live webcast and archived replay of the event may be accessed on the Investors section of the Company's website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Ku
KURA FAQ
6 questionsWhat does Kura Oncology Inc. do?
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute...Where does KURA stock trade?
Kura Oncology Inc. (KURA) is listed on NASDAQ.What sector and industry is KURA in?
Kura Oncology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about KURA?
Kura Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $2300.00 price target on 2026-04-14. Recent price targets range from $1050.00 to $3100.00.What companies are similar to KURA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare KURA side-by-side with any of them on Quantisnow.How can I track KURA on Quantisnow?
Quantisnow aggregates Kura Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KURA to receive live email and push alerts on every new disclosure.